Unreported / Non-Citable
Background
Plaintiffs Kenneth Allard, Rhys Brooks, and Jonathan Otte filed this putative federal securities class action on behalf of investors who purchased publicly traded stock of Jasper Therapeutics, Inc. between November 30, 2023, and January 7, 2026. Jasper is a clinical-stage biotechnology company developing briquilimab, its lead product candidate targeted at mast cell-driven diseases including chronic spontaneous urticaria. The operative amended complaint asserted claims against Jasper, former Chief Executive Officer Ronald A. Martell, Chief Financial Officer Herbert C. Cross, and former Chief Medical Officer Edwin Tucker for securities fraud under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5, alongside controlling-person liability under Section 20(a).
Plaintiffs alleged that defendants misled investors regarding briquilimab's development timeline and clinical progress in its BEACON study, specifically projections that a registrational trial would launch in late 2025. In July 2025, Jasper revealed that 10 of 12 patients in cohorts 8 and 9 failed to respond, initially blaming a bad drug lot before disclosing in December 2025 that 9 non-responders were misdiagnosed and lacked the condition. Jasper subsequently announced corporate restructuring, workforce cuts, and Martell's termination, causing steep stock declines. Defendants moved to dismiss under Rules 9(b) and 12(b)(6) and the PSLRA, and sought judicial notice and incorporation by reference of nine exhibits. At oral argument, the parties agreed to a high-level dismissal order with leave to amend requiring a structured misstatement chart.
The Court’s Holding
United States District Judge Beth Labson Freeman granted defendants' motion to dismiss the amended complaint in its entirety with leave to amend. As a threshold matter, the court granted defendants' unopposed request to consider nine defense exhibits under judicial notice and the incorporation by reference doctrine, concluding that SEC filings are routinely subject to judicial notice and that the press releases and clinical records formed the basis of plaintiffs' allegations.
Addressing Count I, the court held that plaintiffs failed to plead actionable misstatements and falsity under Rule 9(b) and the PSLRA. The complaint set forth 41 paragraphs containing extensive block quotations without identifying which specific assertions were alleged to be false, improperly forcing defendants to guess at the claims. Substantively, plaintiffs failed to allege contemporaneous internal facts showing that projections regarding a 2025 registrational trial were false when made or that defendants knew cohorts 8 and 9 faced heightened misdiagnosis risks. In addition, vague optimistic statements regarding corporate progress constituted nonactionable puffery, while projected trial timelines fell within the PSLRA safe harbor for forward-looking statements accompanied by meaningful cautionary language.
The court further held that plaintiffs failed to plead facts creating a strong inference of scienter under the PSLRA. Allegations concerning anonymous former employees lacked specificity and direct connection to the challenged statements, while generic motives regarding capital needs, executive departures, and core business operations failed to establish intentional deceit or deliberate recklessness. Because plaintiffs failed to plead an underlying primary violation of Section 10(b), the court summarily dismissed Count II for controlling-person liability under Section 20(a). The court granted leave to file a second amended complaint by January 19, 2027, mandating a detailed chart specifying each misstatement, speaker, falsity facts, and scienter facts.
Key Takeaways
- Plaintiffs asserting Section 10(b) claims cannot rely on undifferentiated block quotations and must isolate the specific false statements attributed to each defendant.
- Challenging clinical trial progress requires contemporaneous corporate records showing statements were false when made rather than post-hoc disclosures or conclusory allegations.
- Vague accounts from confidential former employees, executive resignations, and typical capital-raising motives are insufficient to establish a strong inference of scienter under the PSLRA.
- Failure to plead a primary securities fraud violation under Section 10(b) warrants summary dismissal of derivative controlling-person claims under Section 20(a).
- The district court enforced strict procedural compliance by ordering plaintiffs to file an itemized matrix mapping each statement to its speaker, falsity facts, and scienter facts.
Why It Matters
This ruling highlights the stringent pleading hurdles confronting securities class actions in the biopharmaceutical industry. In the Ninth Circuit, plaintiffs cannot rely on retrospective disclosures or generalized allegations of trial flaws; they must provide contemporaneous internal documentation proving corporate officers knew projections or clinical statements were misleading when made.
Furthermore, the required misstatement matrix provides a practical case-management mechanism to resolve sprawling PSLRA complaints, allowing courts to conduct structured, statement-by-statement evaluations without sorting through ambiguous block quotations.